Comparison of assay systems for warfarin-related CYP2C9 and VKORC1 genotyping

Clinica Chimica Acta

Volumn 411, Issue 13-14, 2010, Pages 947-954

  Maurice, Carleta B ^a   Barua, Pankaj K ^a   Simses, Diane ^a   Smith, Penny ^b   Howe, John G ^b   Stack, Gary ^a,b  

^a VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

CYP2C9; Genotyping assays; VKORC1; Warfarin

Indexed keywords

CYTOCHROME P450 2C9; OXIDOREDUCTASE; UNCLASSIFIED DRUG; VITAMIN K EPOXIDE REDUCTASE COMPLEX SUBUNIT 1; WARFARIN;

ALLELE; ARTICLE; BLOOD SAMPLING; CLINICAL LABORATORY; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DIAGNOSTIC ACCURACY; DNA EXTRACTION; GENE IDENTIFICATION; GENETIC VARIABILITY; GENOTYPE; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; PIPETTE; PRIORITY JOURNAL; SAMPLE SIZE; TURNAROUND TIME;

ALGORITHMS; ARYL HYDROCARBON HYDROXYLASES; DATABASES, GENETIC; DNA; DOSE-RESPONSE RELATIONSHIP, DRUG; ETHANOL; GENETIC TECHNIQUES; GENOTYPE; HUMANS; MIXED FUNCTION OXYGENASES; POLYMORPHISM, SINGLE NUCLEOTIDE; TIME FACTORS; WARFARIN;

EID: 77952546324     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2010.03.005     Document Type: Article

References (37)

1. Linkins L.A., Choi P.T., Douketis J.D. Clinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism: a meta-analysis. Ann Intern Med 2003, 139:893-900.
2. Ansell J., Hirst J., Dalen H., et al. Managing oral anticoagulant therapy. Chest 2001, 119:22S-38S.
3. The International Warfarin Pharmacogenetics Consortium Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med 2009, 360:753-764.
4. Wadelius M., Chen L.Y., Lindh J.D., et al. The largest prospective warfarin-treated cohort supports genetic forecasting. Blood 2009, 113:784-792.
5. Bodin L., Verstuyft C., Tregouet D., et al. Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity. Blood 2005, 106:135-140.
6. Zhu Y., Shennan M., Reynolds K.K., et al. Estimation of warfarin maintenance dose based on VKORC1 (-1639 G>A) and CYP2C9 genotypes. Clin Chem 2007, 53:1199-1205.
7. Gage B.F., Eby C., Milligan P.E., et al. Use of pharmacogenetics and clinical factors to predict the maintenance dose of warfarin. Thromb Haemost 2004, 91:87-94.
8. Millican E.A., Lenzini P.A., Milligan P.E., et al. Genetic-based dosing in orthopedic patients beginning warfarin therapy. Blood 2007, 110:1511-1515.
9. Anderson J.L., Horne B.D., Stevens S.M., et al. Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation. Circulation 2007, 116:2563-2570.
10. Wu A.H.B. Use of genetic and nongenetic factors in warfarin dosing algorithms. Pharmacogenetics 2007, 8:851-861.
11. Schelleman H., Chen J., Chen Z., et al. Dosing algorithms to predict warfarin maintenance dose in Caucasians and African Americans. Clin Pharmacol Ther 2008, 84:332-339.
12. Wen M.S., Lee M.T.M., Chen J.J., et al. Prospective study of warfarin dosage requirements based on CYP2C9 and VKORC1 genotypes. Clin Pharmacol Ther 2008, 84:83-89.
13. U.S. Food and Drug Administration (FDA). FDA News. FDA approves updated warfarin (Coumadin) prescribing information. Aug 16, 2007. Accessed May 5, 2008. http://www.fda.gov.
14. Third Wave Technologies Accessed October 1, 2009. http://www.twt.com/clinical/index.html.
15. King C.R., Porche-Sorbet R.M., Gage B.F., et al. Performance of commercial platforms for rapid genotyping of polymorphisms affecting warfarin dose. Am J Clin Pathol 2008, 129:876-883.
16. Langley M.R., Booker J.K., Evans J.P., et al. Comparison of CYP2C9-VKORC1 genotyping assays and warfarin-dosing algorithms. JMD 2009, 11:216-224.
17. Babic N., Haverfield E.V., Burrus J.A., et al. Comparison of performance of three commercial platforms for warfarin sensitivity genotyping. Clin Chim Acta 2009, 406:143-147.
18. Maurice C.B., Barua P.K., Simses D., et al. Comparison of three commercial CYP2C9/VKORC1 genotyping assays for warfarin sensitivity. JMD 2008, 10:566. Abstract G04.
19. Sconce E.A., Khan T.I., Wynne H.A., et al. The impact of CYP2C9 and VKORC1 genetic polymorphisms and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood 2005, 106:2329-2333.
20. Rieder M.J., Reiner A.P., Gage B.F., et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. NEJM 2005, 352:2285-2293.
21. Schelleman H., Chen Z., Kealey C., et al. Warfarin response and vitamin K epoxide reductase complex 1 in African Americans and Caucasians. Clin Pharmacol Ther 2007, 81:742-747.
22. Cell lines typed for CYP2C9 and VKORC1 alleles Accessed June 23, 2008. http://www.cdc.gov/dls/genetics/rmmaterials/materialsavailability.aspx.
23. Limdi N.A., McGwin G., Goldstein J.A., et al. Influence of CYP2C9 and VKORC1 1173C/T genotype on the risk of hemorrhagic complications in African-American and European-American patients on warfarin. Clin Pharmacol Ther 2007, 83:312-321.
24. Limdi N.A., Goldstein J.A., Blaisdell J.A., Beasley T.M., Rivers C.A., Acton R.T. Influence of CYP2C9 genotype on warfarin dose among African-Americans and European-Americans. Personalized Med 2007, 4:157-169.
25. Allabi A.C., Gala J., Desager J., et al. Genetic polymorphisms of CYP2C9 and CYP2C19 in the Beninese and Belgian populations. Br J Clin Pharmacol 2003, 56:653-657.
26. Dickmann L.J., Rettie A.E., Kneller M.B., et al. Identification and functional characterization of a new CYP2C9 variant (CYP2C9*5) expressed among African Americans. Mol Pharmacol 2001, 60:382-387.
27. Tai G., Farin F., Rieder M.J., et al. In-vitro effects of the CYP2C9*11 polymorphism on warfarin metabolism and dose. Pharmacogenet Genomics 2005, 15:475-481.
28. Blaisdell J., Jorge-Nebert L.F., Coulter S., et al. Discovery of new potentially defective alleles of human CYP2C9. Pharmacogenetics 2004, 14:527-537.
29. Online warfarin dosing Accessed August 11, 2009. http://www.WarfarinDosing.org.
30. Caldwell M.D., Awad T., Johnson J.A., et al. CYP4F2 genetic variant alters required warfarin dose. Blood 2008, 111:4106-4112.
31. Wadelius M., Chen L.Y., Downes K., et al. Common VKORC1 and GGCX polymorphisms associated with warfarin dose. Pharmacogenomics J 2005, 5:262-270.
32. Rai A.J., Udar N., Saad R., Fleisher M. A multiplex assay for detecting genetic variations in CYP2C9, VKORC1, and GGCX involved in warfarin metabolism. Clin Chem 2009, 55:823-826.
33. Class 2 recall. Verigene warfarin metabolism nucleic acid test cartridge Accessed July 24, 2009. http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfRes/res.cfm?ID=68369.
34. Sellers T., Kalman L.V. Development of cell lines from the Coriell cell repositories for use as verified quality control materials for genetic testing. JMD 2006, 8:624. Abstract G08.
35. Butz K.G., Kuramoto I.K., Hongo D., et al. Comparison of the performance of GentriSure™ human genomic DNA reference controls and Coriell DNA reference control materials. JMD 2007, 9:653. Abstract G06.
36. Eckman M.H., Rosand J., Greenberg S.M., Gage B.F. Cost-effectiveness of using pharmacogenetic information in warfarin dosing for patients with nonvalvular atrial fibrillation. Ann Intern Med 2009, 150:139-141.
37. xMAP technology applications overview Accessed November 8, 2009. http://www.luminexcorp.com/applications/index.html.